ArticleJournal of experimental & clinical cancer research : CR2025

FSTL3 is a biomarker of poor prognosis and associated with immunotherapy resistance in ovarian cancer.

Maeva Chauvin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.